Processing...
Clinical Trials for Melanoma
Search
Search
There are 169 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
169 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with ECOG 0–1 and measurable, unresectable stage III/IV NRAS-mutant melanoma or other advanced solid tumors refractory to, intolerant of, or declining standard therapy receive oral RLY-8161, a selective NRAS inhibitor designed to suppress RAS–MAPK signaling while sparing KRAS and HRAS. Dose escalation is followed by expansion at the selected recommended dose(s).
ClinicalTrials.gov ID: NCT07584226
TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.
ClinicalTrials.gov ID: NCT07749586
TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma, or advanced uveal melanoma, renal cell, non-small-cell lung, or colorectal cancer after standard therapy or when standard therapy is inappropriate, receive oral VMD-102 monotherapy. VMD-102 is an investigational selective inhibitor of protein kinase C epsilon (PKCε/PRKCE).
ClinicalTrials.gov ID: NCT07636785
TrialFetch AI summary: Adults with advanced solid tumors and no curative option after standard therapy receive intravenous STX-003 alone or with pembrolizumab; expansion cohorts focus on previously treated PD-L1-positive NSCLC and cutaneous melanoma. STX-003 is a lipid nanoparticle–delivered, self-replicating mRNA therapy designed to drive tumor-selective IL-12 expression and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT07751042
TrialFetch AI summary: Adults with previously treated advanced or metastatic solid tumors, ECOG 0–1, measurable disease, and a biopsiable tumor receive intravenous or subcutaneous ST-067, alone, after obinutuzumab pretreatment, or with pembrolizumab. ST-067 is an engineered IL-18 that activates the IL-18 receptor while resisting neutralization by IL-18 binding protein; expansion cohorts focus on melanoma, renal cell, triple-negative breast, non-small cell lung, head and neck squamous cell, and MSI-high cancers.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: Adults with previously treated unresectable stage IIIC/IIID or IV melanoma or stage III/IV NSCLC who have a resectable tumor lesion and separate measurable disease receive autologous tumor-infiltrating lymphocytes (IOV-4001) made from their tumor. The cells are gene-edited to inactivate PD-1, aiming to reduce inhibitory checkpoint signaling.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: Adults with measurable metastatic or unresectable cancer, ECOG 0–1, and no suitable standard treatment option may receive oral NX-1607, a CBL-B inhibitor intended to enhance T-cell antitumor activity. Selected tumor cohorts receive NX-1607 with paclitaxel.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic antigen-rich solid tumors and no more than three prior lines of therapy for advanced disease receive intravenous STAR0602 (invikafusp alfa) monotherapy. This investigational antibody–cytokine fusion targets T-cell receptor Vβ6/Vβ10 subsets and stimulates the IL-2 receptor to expand potentially tumor-reactive T cells.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: Adults with recurrent, unresectable advanced or metastatic cancers harboring eligible KRAS non-G12C, BRAF, CRAF, or NRAS alterations receive oral BDTX-4933, an investigational RAF inhibitor designed to block signaling through active RAF dimers. Dose expansion is limited to patients with radiographically progressing KRAS non-G12C–mutant NSCLC.
ClinicalTrials.gov ID: NCT05786924
TrialFetch AI summary: Adults with recurrent or metastatic GRPR-expressing mCRPC, HR-positive/HER2-negative breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, or NSCLC are eligible if they have a lesion with uptake greater than liver on GRPR imaging; recurrent disease must have progressed after at least two systemic therapies. Participants receive up to four cycles of investigational ²¹²Pb-DOTAM-GRPR1, a GRPR-targeted radiopharmaceutical that delivers DNA-damaging alpha radiation.
ClinicalTrials.gov ID: NCT05283330